Register for OBR daily


FM_ROS_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ADXS $10.00 1.7700 +21.51%
ZIOP $9.12 1.1200 +14.00%
CVM $0.73 0.0584 +8.72%
RDUS $44.48 3.5400 +8.65%
GTXI $0.68 0.0400 +6.25%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VICL $1.04 -0.0400 -3.70%
CRIS $1.89 -0.0550 -2.84%
KERX $13.11 -0.3450 -2.57%
CBMG $16.50 -0.4300 -2.54%
CNDO $2.42 -0.0600 -2.42%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months of Follow-Up

(RXi Pharmaceuticals) June 6, 2011 - NeuVax (E75) demonstrates statistical significance in 3-year Disease Free Survival (DFS) in adjuvant breast cancer, with 0% recurrence in the treated group versus 22.2% in the untreated group.
read press release 



Astellas Announces New Study Results Showing Increased Survival Rate for Metastatic Pancreatic Cancer

(Yahoo! Finance) June 6, 2011 - Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.
read article 



Genta Presents Updated Results of Phase II Trial of Tesetaxel in Patients with Advanced Gastric Cancer

(Pharmabiz.com) June 6, 2011 - Genta Incorporated announced updated interim results from a trial of tesetaxel used as 2nd-line treatment in patients with advanced gastric cancer.
read article 



MDxHealth's MGMT Test Identifies Brain Cancer Patients Likely to Live Longer on Temozolomide Treatment - Phase III Data Presented at ASCO

(Reuters) June 6, 2011 - MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDxTM for Brain) was shown to successfully identify those recently diagnosed glioblastoma patients more likely to live longer and have a longer progression free time period following treatment with temozolomide.
read article 



Teva Announces Successful Results Of Phase III Study Of Its Long-Acting G-CSF Product (Lipegfilgrastim) In Breast Cancer Patients

(TheStreet) June 6, 2011 - Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim (INN; internal code - XM22) achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen’s Neulasta™).
read article 



Eisai and Janssen Announce the Presentation of DACOGEN(R) (decitabine) Data at ASCO from a Phase III Study in Patients with Acute Myeloid Leukemia

(SuperGen) June 6, 2011 - Eisai Inc. and Janssen, a Johnson & Johnson Company, both announced the presentation of data from the DACO-016 trial of DACOGEN® (decitabine) at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO). The data demonstrate a clinical improvement in overall survival in older patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML) as defined by the World Health Organization (WHO).
read press release 



Sexual Dysfunction Supplement Doesn't Improve Sex for Cancer Patients, But Improves Quality of Life

(LAT/Booster Shots blog) June 6, 2011 - A supplement promoted for improving sexual dysfunction in women does not do so in cancer patients, but it does improve their quality of life, researchers said Monday.
read article (free registration required) 



Scientists Identify Genetic Markers for Common Side-Effect of Taxane Chemotherapy

(Cancer Research UK) June 6, 2011 - US scientists have identified genetic markers associated with a common side-effect of taxane-based chemotherapy called peripheral neuropathy.
read press release 



Chemo-Induced Nausea Remains Big Problem, URMC Study Says

(URMC) June 6, 2011 - A large, phase III study of four commonly used drug regimens to treat chemotherapy-induced nausea concluded that while two regimens were better at managing patients’ queasiness, none were totally effective - prompting researchers to advise oncologists that more and better treatments are badly needed.
read press release 



Exelixis Shares Fall on Cancer Drug Safety Concerns

(Reuters) June 6, 2011 - Shares of Exelixis Inc. fell 19 percent on Monday after the company reported data over the weekend showing that its experimental cancer drug caused the deaths of six cancer patients in a clinical trial.
read article 



Colorectal Cancer Drug Zaltrap May Slightly Extend Survival

(LAT/Booster Shots blog) June 6, 2011 - Researchers have found that adding the experimental drug Zaltrap in a chemotherapy regimen may slightly prolong survival in patients with advanced colorectal cancer and slow the progression of the disease, companies Sanofi and Regeneron Pharmaceuticals announced Monday.
read article (free registration required) 



Bayer, Algeta's Prostate Cancer Drug Boosts Survival

(Reuters) June 6, 2011 - A experimental prostate cancer drug from Bayer and its Norwegian biotech partner Algeta helped patients live longer a study showed, sending Algeta's share price up 36 percent on Monday.
read article 



Exelixis Shares Drop As Updated Data Highlight Side-Effect Concerns

(Morningstar/Dow Jones Newswires) June 6, 2011 - Exelixis Inc. shares fell 17% Monday on rising concerns about the side effects and deaths reported in the company's update on its cancer drug cabozantinib.
read article 



Cancer Costs Put Treatments Out of Reach for Many

(Reuters) June 6, 2011 - The skyrocketing cost of new cancer treatments is putting advances in fighting the deadly disease out of reach for a growing number of Americans.
read article 



ZALTRAPTM (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients

(Sanofi) June 6, 2011 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that data showing that the investigational agent ZALTRAPTM (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011.
read press release 



Ariad-Merck Cancer Drug for Bones-Tissue Extends Patient Lives in Study

(Bloomberg) June 6, 2011 - Ariad Pharmaceuticals Inc.’s most-advanced experimental medicine extended the lives of sarcoma patients and reduced the risk of the disease progressing, according to a study presented today.
read article 



Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone

(Bayer) June 6, 2011 – Bayer Healthcare today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer’s investigational compound Alpharadin (radium-223 chloride), which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases met its primary endpoint by significantly improving overall survival.
read press release 



Thoughts from Saturday at the Annual Meeting

(ASCO Connection blog) June 5, 2011 - As Saturday at the Annual Meeting has now come to a close, I would like to share a few thoughts:
read article 



A One-in-a-Billion Chance at Success

(CureToday.com blog) June 5, 2011 - What if you could count tiny bits of tumor in the bloodstream to predict whether a drug is working against cancer, rather than measuring the tumor itself?
read article 



Editorial: Tobacco Regulation: Kneecapping the FDA

(Los Angeles Times) June 5, 2011 - Legislation that would weaken the FDA's regulation of cigarettes is a mistake.
read article (free registration required) 



Side Effects? These Drugs Have a Few

(New York Times) June 4, 2011 - Dr. Jon Duke of Indiana University was trying to figure out why his patient’s blood platelets were abnormal. Could it be a side effect of one of the dozen drugs the man was taking, a number that is not uncommon among elderly people?
read article 



New Chemotherapy Scheduling Improves Survival for Most Common Form of Childhood Leukemia

(NCI News Note) June 5, 2011 - New NCI-sponsored clinical trial results reported today at the annual American Society of Clinical Oncology meeting in Chicago show that, in a high-risk form of pediatric acute lymphoblastic leukemia (ALL), a high-dose schedule of a drug raises already high cure rates even higher.
read article  



Additional Notable Research Advances Presented at 2011 ASCO Annual Meeting

(ASCO) June 5, 2011 - In addition to the abstracts featured in the official 2011 ASCO Annual Meeting Press Program, nine noteworthy studies on the prevention, screening, evaluation and management of several types of cancers were highlighted at the meeting. The 2011 ASCO Annual Meeting is being held June 3-7 at McCormick Place in Chicago.
read press release 



NY Bill Would Reduce Costs on Oral Chemotherapy

(Seattle Post-Intelligencer/AP) June 5, 2011 - Megan Bonstein says modern health care has provided her oral chemotherapy in a pill to fight her leukemia, but modern health insurance has failed her.
read article 



Thoughts from Saturday at the Annual Meeting

(ASCO Connection blog) June 5, 2011 - As Saturday at the Annual Meeting has now come to a close, I would like to share a few thoughts:
read article